Literature DB >> 20152525

Immunotherapy for prostate cancer: an emerging treatment modality.

Charles G Drake1.   

Abstract

This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies. Copyright (c) 2010. Published by Elsevier Inc.

Entities:  

Mesh：

Year:  2010        PMID： 20152525      PMCID： PMC4886226          DOI： 10.1016/j.ucl.2009.11.001

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  77 in total

1.  Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Authors:  M G Sanda; D C Smith; L G Charles; C Hwang; K J Pienta; J Schlom; D Milenic; D Panicali; J E Montie
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

2.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

Authors:  Neil H Bander; Matthew I Milowsky; David M Nanus; Lale Kostakoglu; Shankar Vallabhajosula; Stanley J Goldsmith
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

Review 3.  Immune-based therapies for prostate cancer.

Authors:  Douglas G McNeel; Miroslav Malkovsky
Journal:  Immunol Lett       Date:  2005-01-15       Impact factor: 3.685

4.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

Authors:  Douglas G McNeel; Edward J Dunphy; James G Davies; Thomas P Frye; Laura E Johnson; Mary Jane Staab; Dorothea L Horvath; Jane Straus; Dona Alberti; Rebecca Marnocha; Glenn Liu; Jens C Eickhoff; George Wilding
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

7.  Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.

Authors:  Kathleen Ebelt; Gregor Babaryka; Bernhard Frankenberger; Christian G Stief; Wolfgang Eisenmenger; Thomas Kirchner; Dolores J Schendel; Elfriede Noessner
Journal:  Eur J Cancer       Date:  2009-03-21       Impact factor: 9.162

8.  Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

Authors:  Satoshi Wada; Kiyoshi Yoshimura; Edward L Hipkiss; Tim J Harris; Hung-Rong Yen; Monica V Goldberg; Joseph F Grosso; Derese Getnet; Angelo M Demarzo; George J Netto; Robert Anders; Drew M Pardoll; Charles G Drake
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

9.  Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.

Authors:  Brian Schurko; William K Oh
Journal:  Nat Clin Pract Oncol       Date:  2008-07-22

10.  PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

Authors:  Brant A Inman; Thomas J Sebo; Xavier Frigola; Haidong Dong; Eric J Bergstralh; Igor Frank; Yves Fradet; Louis Lacombe; Eugene D Kwon
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860
View more
  5 in total

1.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Authors:  Eugene D Kwon; Charles G Drake; Howard I Scher; Karim Fizazi; Alberto Bossi; Alfons J M van den Eertwegh; Michael Krainer; Nadine Houede; Ricardo Santos; Hakim Mahammedi; Siobhan Ng; Michele Maio; Fabio A Franke; Santhanam Sundar; Neeraj Agarwal; Andries M Bergman; Tudor E Ciuleanu; Ernesto Korbenfeld; Lisa Sengeløv; Steinbjorn Hansen; Christopher Logothetis; Tomasz M Beer; M Brent McHenry; Paul Gagnier; David Liu; Winald R Gerritsen
Journal:  Lancet Oncol       Date:  2014-05-13       Impact factor: 41.316

Review 2.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

Review 3.  Immunotherapy for the treatment of prostate cancer.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Philip W Kantoff
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

4.  Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse.

Authors:  C D Lemke; J B Graham; D M Lubaroff; A K Salem
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-01-25       Impact factor: 5.554

Review 5.  Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy.

Authors:  Lisa M Farzad; Masataka Suzuki
Journal:  Biomedicines       Date:  2014-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.